631 related articles for article (PubMed ID: 12555216)
1. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
2. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
7. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
8. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
Kattamis A; Lagona E; Orfanou I; Psichou F; Ladis V; Kanavakis E; Metaxotou-Mavrommati A; Kattamis C
Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
10. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations.
Sebastiani P; Wang L; Nolan VG; Melista E; Ma Q; Baldwin CT; Steinberg MH
Am J Hematol; 2008 Mar; 83(3):189-95. PubMed ID: 17918249
[TBL] [Abstract][Full Text] [Related]
11. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
12. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
13. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
14. [Hydroxyurea, erythrocyte volumes and hemoglobin F].
Bargetzi MJ; Schönenberger A; Tichelli A; Passweg J; Rabaglio M; Singer D; Sissolak G; Gratwohl A; Speck B
Schweiz Med Wochenschr; 1995 Mar; 125(9):433-5. PubMed ID: 7534433
[TBL] [Abstract][Full Text] [Related]
15. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
16. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
17. Dominant influence of gamma-globin promoter polymorphisms on fetal haemoglobin expression in sickle cell disease.
Ofori-Acquah SF; Lalloz MR; Serjeant G; Layton DM
Cell Mol Biol (Noisy-le-grand); 2004 Feb; 50(1):35-42. PubMed ID: 15040425
[TBL] [Abstract][Full Text] [Related]
18. Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes.
Ofori-Acquah SF; Lalloz MR; Layton DM
Biochem Biophys Res Commun; 1999 Jan; 254(1):181-7. PubMed ID: 9920754
[TBL] [Abstract][Full Text] [Related]
19. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
Koc A; Gumruk F; Gurgey A
Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
[TBL] [Abstract][Full Text] [Related]
20. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Rodgers GP; Dover GJ; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1990 Apr; 322(15):1037-45. PubMed ID: 1690857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]